Company intelligence / Profile preview

DairyX

Ownership: Private
Development stage: Preclinical

Overview

DairyX has developed a precision fermentation process to produce animal-free casein micelles that closely mimic the structure and function of traditional dairy proteins. Their technology enables the creation of authentic-tasting and functional dairy alternatives. They are currently scaling up production, refining processes for cost efficiency, collaborating with established dairy companies on product integration, and preparing for regulatory approval under GRAS status. Commercial availability is targeted for early 2027.

Modalities: Recombinant proteinPrecision fermentation
Industry: Food & Nutrition

Partnerships

Collaborations with established dairy companies to test and integrate their animal-free gelling caseins into existing manufacturing processes

Beyond the preview

Go deeper on DairyX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DairyX.

Explore the full profile